Board of Directors

Peter is a Founding Partner at Fairmount Funds Management LLC, a healthcare investment firm he co-founded in April 2016. Prior to Fairmount, he was a member of the investment team at Boxer Capital, LLC, an investment fund that was part of the Tavistock Group, based in San Diego. Peter also serves as chairman of the board of directors of Cogent Biosciences, Inc. (Nasdaq: COGT) and is a member of the board of directors of Apogee Therapeutics, Inc. (Nasdaq: APGE), Spyre Therapeutics, Inc. (Nasdaq: SYRE), Oruka Therapeutics, Inc. (Nasdaq: ORKA), and Crescent Biopharma, Inc. (Nasdaq: CBIO). He received a B.B.A. from Emory University.

Jennifer Jarrett is Chief Executive Officer of Damora Therapeutics. She is a seasoned executive with nearly three decades of experience in corporate strategy, finance and investor relations, drug development, and organizational leadership. Most recently, she served as Chief Operating Officer of Arcus Biosciences, a development-stage oncology company. During her tenure, she also served as Chief Financial Officer and a member of the company’s Board of Directors. Prior to Arcus, Ms. Jarrett served as Vice President of Corporate Development and Capital Markets at Uber Technologies, Inc. Previously, she was Chief Financial Officer of Medivation, a commercial oncology company that developed the blockbuster medicine XTANDI® (enzalutamide) for prostate cancer, through the company’s acquisition by Pfizer. Ms. Jarrett spent 20 years in investment banking, including at Citigroup, where she ran the firm’s west coast life sciences investment banking practice, and prior to that at Credit Suisse and Donaldson, Lufkin & Jenrette. Ms. Jarrett received a B.A. in Economics from Dartmouth College and an M.B.A. from Stanford University Graduate School of Business. She serves on the boards of Sagimet Biosciences, Syndax Pharmaceuticals and Zura Bio.

Julianne is a Growth Partner at Fairmount Funds Management LLC. Prior to joining Fairmount, she was a pivotal member of the CRISPR Therapeutics leadership team. During her six-year tenure with CRISPR, she served as the Program Leader across multiple hematology and oncology programs before taking on the role of Chief Operating Officer. In these roles, she oversaw the development of Casgevy™ and helped mature the operating model of the company. Julianne has also worked as a leader in the life sciences practice at McKinsey & Co. She received her A.B. from Princeton University and an MBA from the Wharton School, University of Pennsylvania.

Dr. Cain is the Director of Research at Fairmount Funds Management LLC. Prior to joining Fairmount in 2020, Dr. Cain served in various positions at the healthcare funds at Samsara BioCapital, Apple Tree Partners, and RA Capital Management, where he invested in both public and emerging private biotechnology companies. Dr. Cain has also served as a writer and editor at BioCentury Publications. He also serves as a director of Viridian Therapeutics, Inc. (Nasdaq: VRDN), Cogent Biosciences, Inc. (Nasdaq: COGT) and Jade Biosciences, Inc. (Nasdaq: JBIO). Dr. Cain received a B.A. from the University of California, Santa Barbara and a Ph.D. in Biochemistry and Molecular Biology from the University of California, San Francisco.

Dr. Cameron Turtle is an experienced leader in building, financing, and shaping biopharma organizations from preclinical development to late-stage clinical trials and commercialization. Dr. Turtle currently serves as the Chief Executive Officer of Spyre Therapeutics. Previously, he served as Venture Partner at Foresite Labs, Chief Strategy Officer of BridgeBio Pharma and Chief Business Officer of Eidos Therapeutics. Prior to joining Eidos, he was a consultant at McKinsey & Company. Dr. Turtle received a B.S. with honors in bioengineering from the University of Washington and a D.Phil. in cardiovascular medicine from the University of Oxford, St. John’s College, where he was a Rhodes Scholar.

Michael Landsittel has broad biotech experience spanning strategic finance, corporate and business development, investor relations and organizational leadership. For more than a decade, Mr. Landsittel led strategic finance and operations functions at Blueprint Medicines, most recently as Chief Financial Officer, through the company’s acquisition by Sanofi. While at Blueprint, he led efforts to raise approximately $4 billion in capital through a variety of transactions and helped lead the company’s transition to a commercial immunology company with the launch of AYVAKIT® (avapritinib). Prior to joining Blueprint, he served as Senior Director of Finance at Algeta ASA, through the company’s acquisition by Bayer, and held financial planning, business development and corporate strategy roles at Infinity Pharmaceuticals and Genzyme Corporation. Mr. Landsittel received a B.B.A. from the University of Michigan and an M.B.A. from the Tuck School of Business at Dartmouth College.